

HAB HIV Core Clinical Performance Measures for Adult/Adolescent Clients: Group 1



| Performance Measure: PCP Prophylaxis | | OPR-Related Measure: Yes www.hrsa.gov/performance/measure/pcp.htm | | | | | | | | | | | | | | | | | | | | | | |
|--|--|---|-------|-------|--|------|------|------|------|---------|------|------|------|------|---------|------|------|------|------|---------|-------|-------|-------|-------|
| Percentage of clients with HIV infection and a CD4 T-cell count below 200 cells/mm ³ who were prescribed PCP prophylaxis | | | | | | | | | | | | | | | | | | | | | | | | |
| Numerator: | Number of HIV-infected clients with CD4 T-cell counts below 200 cells/mm ³ who were prescribed PCP prophylaxis | | | | | | | | | | | | | | | | | | | | | | | |
| Denominator: | Number of HIV-infected clients who: <ul style="list-style-type: none"> had a medical visit with a provider with prescribing privileges¹, i.e. MD, PA, NP at least once in the measurement year, and had a CD4 T-cell count below 200 cells/mm³ | | | | | | | | | | | | | | | | | | | | | | | |
| Patient Exclusions: | <ol style="list-style-type: none"> Patients with CD4 T-cell counts below 200 cells/mm³ repeated within 3 months rose above 200 cells/mm³ Patients newly enrolled in care during last three months of the measurement year | | | | | | | | | | | | | | | | | | | | | | | |
| Data Element: | <ol style="list-style-type: none"> Is the client HIV-infected? (Y/N) <ol style="list-style-type: none"> If yes, was the CD4 T-cell count <200 cells/mm³? (Y/N) <ol style="list-style-type: none"> If yes, was PCP prophylaxis prescribed? (Y/N) <ol style="list-style-type: none"> If no, was the CD4 count repeated within 3 months? (Y/N) <ol style="list-style-type: none"> If yes, did it remain below 200 cells/mm³? (Y/N) <ol style="list-style-type: none"> If yes, was PCP prophylaxis prescribed? (Y/N) | | | | | | | | | | | | | | | | | | | | | | | |
| Data Sources: | <ul style="list-style-type: none"> Electronic Medical Record/Electronic Health Record CAREWare, Lab Tracker, or other electronic data base HIVQUAL reports on this measure for grantee under review Medical record data abstraction by grantee of a sample of records | | | | | | | | | | | | | | | | | | | | | | | |
| National Goals, Targets, or Benchmarks for Comparison: | IHI Goal: 95% ² National HIVQUAL Data ³ : <table border="1" style="margin-left: 20px;"> <thead> <tr> <th></th> <th>2003</th> <th>2004</th> <th>2005</th> <th>2006</th> </tr> </thead> <tbody> <tr> <td>Top 10%</td> <td>100%</td> <td>100%</td> <td>100%</td> <td>100%</td> </tr> <tr> <td>Top 25%</td> <td>100%</td> <td>100%</td> <td>100%</td> <td>100%</td> </tr> <tr> <td>Median*</td> <td>93.3%</td> <td>90.9%</td> <td>92.3%</td> <td>94.4%</td> </tr> </tbody> </table> <small>*from HAB data base</small> | | | | | 2003 | 2004 | 2005 | 2006 | Top 10% | 100% | 100% | 100% | 100% | Top 25% | 100% | 100% | 100% | 100% | Median* | 93.3% | 90.9% | 92.3% | 94.4% |
| | 2003 | 2004 | 2005 | 2006 | | | | | | | | | | | | | | | | | | | | |
| Top 10% | 100% | 100% | 100% | 100% | | | | | | | | | | | | | | | | | | | | |
| Top 25% | 100% | 100% | 100% | 100% | | | | | | | | | | | | | | | | | | | | |
| Median* | 93.3% | 90.9% | 92.3% | 94.4% | | | | | | | | | | | | | | | | | | | | |
| Outcome Measures for Consideration: | <ul style="list-style-type: none"> Rate of PCP in the measurement year Mortality rates Cost savings | | | | | | | | | | | | | | | | | | | | | | | |
| Basis for Selection and Placement in Group 1: | | | | | | | | | | | | | | | | | | | | | | | | |
| Pneumocystis pneumonia (PCP) is the most common opportunistic infection in people with HIV. Without treatment, over 85% of people with HIV would eventually develop PCP. It is a major cause of mortality among persons with HIV infection, yet is almost entirely preventable and treatable. Pneumocystis almost always affects the lungs, causing a form of pneumonia. People with CD4 T-cell counts under 200 cells/mm ³ | | | | | | | | | | | | | | | | | | | | | | | | |